Chemoprevention

  • W. Weber
  • S. Kubba
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

With the aging of the population cancer mortality is increasing. Cancer treatment is making progress - steadily but slowly. Therefore, the therapy for late disease needs to be complemented by other approaches. In recent years, the possibility has been raised that pharmacologic agents or nutritional modification can prevent the development of human neoplasia, slow down its progression, or make it regress. Basic research has corroborated this concept [1], and clinical trials have shown that chemopreventive agents can be effective in controlling oral leukoplakia, [2,3], solar keratosis [4], skin cancer [5] and second primary head and neck squamous cell carcinomas [6]. High fibre intake leads to a decrease in the number of polyps in patients with familial adenomatous polyposis [7]. The initial choice of chemopreventive agents for clinical trials has been limited to a few compounds and has been dictated by epidemiologic and laboratory data available in the late 1970s and by the rigid requirement of the use of a “safe” compound in normal or nearly normal populations [8].

Keywords

Placebo Toxicity Oncol Folic Acid Tamoxifen 

References

  1. 1.
    Bertram JS, Kolonel LN, Meyskens FL Jr: Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987 (47):3012–3031PubMedGoogle Scholar
  2. 2.
    Hong WK, Endicott J, Itri LM et al: 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986 (315):1501–1505PubMedCrossRefGoogle Scholar
  3. 3.
    Garewal HS, Meyskens FL Jr, Killen D et al: Response of oral leukoplakia to beta carotene. J Clin Oncol 1990 (8):1715–1720PubMedGoogle Scholar
  4. 4.
    Moriarty M, Dunn J, Darragh A et al: Etretinate in the treatment of actinic keratosis. Lancet 1982 (1):364–365PubMedCrossRefGoogle Scholar
  5. 5.
    Moshell AN: Preventionof skin cancer in xeroderma pigmentosum with oral isotretinoin. Cutis 1989 (43):485–490PubMedGoogle Scholar
  6. 6.
    Hong WK, Lippman SM, Loretta Ml et al: Prevention of second primary tumours with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990 (323)795–801PubMedCrossRefGoogle Scholar
  7. 7.
    De Cosse JJ, Miller HH, Lesser ML: Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. JNCI 1989 (81):1290–1297Google Scholar
  8. 8.
    Boone CW, Kelloff GJ, Malone WE: Identification of candidate cancer chemoprevention agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990 (50):2–9PubMedGoogle Scholar
  9. 9.
    Meyskens FL, Jr: Coming of age -the chemoprevention of cancer. N Engl J Med 1990 (323):825–827PubMedCrossRefGoogle Scholar
  10. 10.
    Lippman SM, Lee JS, Lotan R, Hittelman W, Wargowich MJ, Hong WK: Biomarkers as intermediate end points in chemoprevention trials. JNCI 1990 (82):555–560PubMedGoogle Scholar
  11. 11.
    Steel M, Thompson A, Clayton J: Genetic aspects of breast cancer. Br Med Bull 1991 (47):504–518PubMedGoogle Scholar
  12. 12.
    Houlston RS, Murday V, Harocopos C, Williams CB, Slack J: Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. Br Med J 1990 (301):366–368CrossRefGoogle Scholar
  13. 13.
    Fentiman LS: Breast cancer prevention with tamoxifen. Eur J Cancer 1990 (26):655–656PubMedCrossRefGoogle Scholar
  14. 14.
    Powles TJ, Hardy JR, Ashley SE et al: A pilot trial to evaluate the acute toxicity and feasability of tamoxifen for prevention of breast cancer. Br J Cancer 1989 (60):126–131PubMedCrossRefGoogle Scholar
  15. 15.
    Lippman SM and Hong WK: Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Rad Oncol Biol Phys 1989 (17):691–694CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • W. Weber
    • 1
  • S. Kubba
    • 1
  1. 1.Clinical Cancer Aetiology UnitBaselSwitzerland

Personalised recommendations